List view / Grid view

News

Study comparing Opdivo (nivolumab) to chemotherapy in treatment naïve advanced melanoma patients marks first PD-1 immune checkpoint inhibitor to demonstrate a survival benefit in a Phase 3 trial

17 November 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418)...